Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 20, 2006American Journal of TransplantationOpen Access

Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMark D. PescovitzNational Institute of Allergy and Infectious Diseases

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mark D. Pescovitz (2006) studied this question.

synapsesocial.com/papers/6a70d5e722b3175134db5875https://doi.org/10.1111/j.1600-6143.2006.01288.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX1742005 · 94 citations
  2. 2Treatment of monomorphic B‐cell lymphoma with rituximab after liver transplantation in a child2003 · 16 citations
  3. 3Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial2005 · 203 citations
  4. 4Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.1998 · 2,771 citations